Ramesh Vemuri
Psychiatry · Crystal Lake, ILNPI 1164508149
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 149 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $896 and has fallen 87.5% since, to $112 in 2024.
Across 149 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$367
- AbbVie$349
- Johnson & Johnson$341
- Vanda Pharmaceuticals Inc.$239
- Takeda Pharmaceuticals U.S.A., Inc.$230
- Alkermes, Inc.$194
- plus $825 from 17 others
What the payments were for
- Food & beverage$2,545100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 22 | $367 |
| AbbVie(2 entities) | 22 | $349 |
| Johnson & Johnson | 18 | $341 |
| Vanda Pharmaceuticals Inc. | 10 | $239 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $230 |
| Alkermes, Inc. | 11 | $194 |
| Lundbeck LLC | 12 | $188 |
| Sunovion Pharmaceuticals Inc. | 8 | $79 |
| Tris Pharma Inc | 5 | $74 |
| Teva Pharmaceuticals USA, Inc. | 4 | $71 |
| Acadia Pharmaceuticals Inc | 3 | $65 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $63 |
| Orexo US, Inc. | 2 | $44 |
| Brainsway USA Inc | 1 | $43 |
| Neurocrine Biosciences, Inc. | 2 | $33 |
| Bausch Health US, LLC | 2 | $31 |
| Indivior Inc. | 2 | $28 |
| Neos Therapeutics, LP | 2 | $24 |
| Corium, LLC | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Neuronetics, Inc. | 1 | $13 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
How this compares
$2,545 in reported general payments places this provider in the 85th percentile of 1,344 psychiatry providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $108,591 |
| Clozapine | 12 | $421 |
| Divalproex Sodium | 15 | $354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $33 | $108,59113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Crystal Lake
- Aftab PoshniCrystal Lake$15K
- Michael FeldNorthbrook$1.1M
- Jose MontesRockford$882K
- Mitchell GlaserChicago$752K
- Roukan JazayerliOrland Park$597K
- Ming XuBourbonnais$505K
- Peter WeidenChicago$440K
- Michelle DeesChicago$289K
- Mark ShukhmanSkokie$250K
- Abid NazeerOak Brook$228K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.